Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).
Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
For information on effects of treatment and patient populations studied in clinical trials please see Pharmacology: Pharmacodynamics under Actions.
Limitations of Use: Dutasteride-containing products, including Duodart, are not approved for the prevention of prostate cancer.